Welcome to VIRTTU

VIRTTU Biologics is a clinical stage biotechnology company pioneering the development of viruses to treat cancer.

By remodeling a common virus we have developed and patented a series of novel therapies that have the potential to transform treatment and target many forms of cancer effectively.

Our most advanced programme, a unique cancer-destroying (oncolytic) virus, has the potential to radically change oncology therapy through its ability to seek out and multiply only in cancer cells: destroying them while leaving healthy cells unaffected.

We are now actively advancing the clinical development programme required to secure regulatory approval to market our lead programme, SEPREHVIR®, for use in cancer therapy.